News By Tag
* More Industries...
News By Location
Progression of biomarkers for Alzheimer’s disease – 5th & 6th November London
Paving the way of using AD biomarkers as supportive evidence of disease modifying treatment effects
Clinical trials are still an important area of discussion, with increasing efficiency in R&D and clinical trials as an essential part of the pharma industry. Clinical trials in the CNS industry must therefore operate a minefield of varying regulations and logistical difficulties, in order to develop a drug from discovery to market.
Johan Luthman, Senior Programme Leader Merck & Co. will speak at SMi’s Clinical Trials in CNS event held in London on the 5th & 6th November on the new opportunities to follow brain function and dysfunction a research on Alzheimers’s disease. He will discuss the critical AD biomarker validation and qualification work done via public-private pre competitive partnerships and detecting very early stages of AD pathology and following the disease progression with new technologies.
Register today to hear about the current development in neurodegenerative treatments from top pharma companies and academics. For further information and to register visit http://www.smi-